PDS Biotech receives U.S. patent allowance for PDS0101 with 20-year market protection

PDS Biotechnology Corp

U.S. Patent Office issued Notice of Allowance for PDS0101 (Application 16/210,750) covering cationic lipid compositions.
New patent plus biologics exclusivity expected to provide ~20 years of market protection for PDS0101.
PDS0101 is in Phase 3 VERSATILE-003 trial for HPV16-positive head and neck cancers.
Company submitted FDA protocol amendment proposing PFS as primary endpoint for potential accelerated approval.
IP estate includes granted patents in U.S., Europe, Japan, China, Australia, Canada, Israel, Mexico, and Hong Kong.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.